Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice

The aim of this paper is to study preventive effect of cytotoxic lectin from Bacillus subtilis B-7025 on the tumor growth and nonspecific immunity in sarcoma 37 transplanted mice.

Збережено в:
Бібліографічні деталі
Дата:2010
Автори: Tanasienko, O.A., Rudyk, M.P., Pozur, V.V., Potebnya, G.P.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2010
Назва видання:Experimental Oncology
Теми:
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/32305
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice / O.A. Tanasienko, M.P. Rudyk, V.V. Pozur, G.P. Potebnya // Experimental Oncology. — 2010. — Т. 32, № 4. — С. 254–257. — Біліогр.: 29 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id irk-123456789-32305
record_format dspace
spelling irk-123456789-323052013-02-13T03:31:15Z Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice Tanasienko, O.A. Rudyk, M.P. Pozur, V.V. Potebnya, G.P. Original contributions The aim of this paper is to study preventive effect of cytotoxic lectin from Bacillus subtilis B-7025 on the tumor growth and nonspecific immunity in sarcoma 37 transplanted mice. 2010 Article Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice / O.A. Tanasienko, M.P. Rudyk, V.V. Pozur, G.P. Potebnya // Experimental Oncology. — 2010. — Т. 32, № 4. — С. 254–257. — Біліогр.: 29 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/32305 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Original contributions
Original contributions
spellingShingle Original contributions
Original contributions
Tanasienko, O.A.
Rudyk, M.P.
Pozur, V.V.
Potebnya, G.P.
Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice
Experimental Oncology
description The aim of this paper is to study preventive effect of cytotoxic lectin from Bacillus subtilis B-7025 on the tumor growth and nonspecific immunity in sarcoma 37 transplanted mice.
format Article
author Tanasienko, O.A.
Rudyk, M.P.
Pozur, V.V.
Potebnya, G.P.
author_facet Tanasienko, O.A.
Rudyk, M.P.
Pozur, V.V.
Potebnya, G.P.
author_sort Tanasienko, O.A.
title Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice
title_short Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice
title_full Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice
title_fullStr Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice
title_full_unstemmed Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice
title_sort influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2010
topic_facet Original contributions
url http://dspace.nbuv.gov.ua/handle/123456789/32305
citation_txt Influence of bacterial lectins on some reactions of nonspecific immunity in sarcoma 37 transplanted mice / O.A. Tanasienko, M.P. Rudyk, V.V. Pozur, G.P. Potebnya // Experimental Oncology. — 2010. — Т. 32, № 4. — С. 254–257. — Біліогр.: 29 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT tanasienkooa influenceofbacteriallectinsonsomereactionsofnonspecificimmunityinsarcoma37transplantedmice
AT rudykmp influenceofbacteriallectinsonsomereactionsofnonspecificimmunityinsarcoma37transplantedmice
AT pozurvv influenceofbacteriallectinsonsomereactionsofnonspecificimmunityinsarcoma37transplantedmice
AT potebnyagp influenceofbacteriallectinsonsomereactionsofnonspecificimmunityinsarcoma37transplantedmice
first_indexed 2025-07-03T12:49:13Z
last_indexed 2025-07-03T12:49:13Z
_version_ 1836630099045122048
fulltext 254 Experimental Oncology 32, 254–257, 2010 (December) Lectins are the proteins widely distributed in nature and isolated from animal and human tissues as well as from plants, viruses and bacteria. The characteristic feature of these biopolymers consists in their ability to recognize specifically and bind reversibly to glycoside structures in the complexes that contain carbohydrates. Lectins are highly stable and multifunctional molecules and may be isolated from various sources as well as produced by recombinant technology. It is important also that their reactions with soluble compounds and cells may be reversible in the presence of simple sugars. The majority of lectins studied up to date possesses hemagglutinating activity, and some of them cause agglutination of malignant, embryonic cells, yeast and bacteria [1], and demonstrate antitumor activity and immunomodulating effects [2–4]. For example, the mitogenic effect of lectins toward T-lymphocytes, their ability to stimulate the production of various cy- tokines, in particular TNF-α, IFN-γ, IFN-α, proinflam- matory interleukins (IL-1α, IL-1β, IL-6, IL-12), have been revealed. There are some reports on stimulating effects of lectins on macrophages and granulocytes [5, 6]. Such biologic properties of lectins are considered as potentially important ones for the therapy of various pathologies related to immune system disorders and cancer. Immunomodulating effects of lectins [7, 8] may be promising in cancer treatment, in particular for the pre- vention of metastasizing after the surgical removal of tumor. Therefore, the cytotoxic lectins as unique im- munomodulators with targeted action [9–11] are ad- vantageous for the development of novel preparations for vector therapy of malignant tumors. The complex of means for elevation of immunoreactivity in combina- tion with immunotherapy may significantly elevate an efficacy of treatment and improve the quality of life of cancer patients. It is known that anticancer action of many lectins of plant and fungal origin is realized via their immuno- modulating properties. Recently, the study of the lec- tins of bacterial origin has been initiated. In this regard, of special interest is the group of extracellular lectins of saprophytic bacteria from genus Bacillus with a rare specificity toward acidic carbohydrates, in particular glucuronic, N-acetyl- and N-glycolylneuraminic acids, fructose-1,6-diphosphate [12], which is unusual for lectins of plant and animal origin. We have earlier shown that the binding of cytotoxic lectins (CL) from B.subtilis B-7025 to cell surface recep- tors modifies tumor-associated antigens elevating their immunogenicity, which may be advantageous for the de- velopment and generation of anticancer vaccines [13, 14]. However, antitumor and immunomodulating properties CL from B.subtilis B-7025 in itself, have not been yet studied. An established preventive anticancer effect of CL from B.subtilis B-7025 in experimental tumors of different genesis [15] has forced us to study immunomodulating properties of the preparation using experimental tumor models. The present work was aimed at studying pre- ventive antitumor affect of CL from B.subtilis B-7025 on the tumor growth and nonspecific immunity in sarco- ma-37 transplanted mice. MATERIALS AND METHODS The cytotoxic lectins were isolated from cultural fluid of B. subtilis strain B-7025 registered in the col- lection of Institute of Microbiology and Virology NAS of Ukraine [16] by the method developed by us ear- INFLUENCE OF BACTERIAL LECTINS ON SOME REACTIONS OF NONSPECIFIC IMMUNITY IN SARCOMA 37 TRANSPLANTED MICE O.A. Tanasienko1*, M.P. Rudyk2, V.V. Pozur2, G.P. Potebnya1 1R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Vasylkivska 45, Kyiv 01601, Ukraine 2T.G. Shevchenko Kyiv National University, Volodymirska 64, Kyiv 01033, Ukraine Aim: To study preventive effect of cytotoxic lectin from Bacillus subtilis B-7025 on the tumor growth and nonspecific immunity in sarcoma 37 transplanted mice. Methods: Sarcoma 37 cells were transplanted in Balb/c mice. Cytotoxic lectin (CL) was isolated from cultural fluid of B.subtilis strain B-7025 and inoculated at a dose of 0.2 mg per animal in prophylactic or combined sched- ule. Functional activity of macrophages was evaluated by NBT-test and the level of cytotoxicity, cytotoxic activity of splenocytes was assayed against K562 cells. Results: CL administration in prophylactic or combined schedule results in inhibition of sarcoma 37 growth in mice. Stimulating effect of CL on peritoneal macrophages of sarcoma 37-bearing mice, especially at early stages of tumor growth, has been observed. At the late stage of tumor growth, the effect of lectin on cytotoxic activity of spleen mononuclear cells has been registered. Conclusion: Upon the use of lectin from B. subtilis B-7025, positive shifts of antitumor immunity reactions leading to tumor growth inhibition and elevation of average life span of tumor-bearing mice, have been detected. Key Words: cytotoxic lectin, sarcoma 37, peritoneal macrophages, splenocytes, cytotoxic activity. Received: April 25, 2010. *Correspondence: E-mail: iris@onconet.kiev.ua, rosiente@gmail.com; Fax: +380442581656 Abbreviations used : ALS — average life span; CL — cytotoxic lectin; IFN — interferon; IL — interleukin; MI — modulation index; NBT — nitroblue tetrazolium; PMp — peritoneal macrophage; PS — physiologic saline; TCT — tumor cell transplantation; TGI — tumor growth inhibition; TNF — tumor necrosis factor. Exp Oncol 2010 32, 4, 254–257 Experimental Oncology 32, 254–257, 2010 (December) 255 lier [12]. Isolated and purified cytotoxic lectins are thermostable glycoproteins with isoelectric points of 3.6 and 4.4 units possessing molecular mass poly- morphism caused by formation of multiple forms of the biopolymer [17]. 2-2.5-months old female Balb/c mice were used in the study. The animals were injected subcutaneously with CL (0.2 mg per animal) 4 times with 1–2 days in- tervals. The next day after the last CL administration, 0.5 x 106 sarcoma 37 cells were grafted in the thigh muscle of both experimental and control animals. For prophylactic schedule of treatment with CL, animals were housed in 2 groups: mice from 1st group were further treated with CL (0.05 mg per animal) twice a week for 3 weeks (combined scheme), while mice from 2nd experimental group (prophylactic scheme) and control animals received physiologic solution. Using a caliper, the tumor diameters were measured daily, and tumor volumes were calculated using the following formula: V = D × d2 × 0.52 (V, tumor volume; D, the largest dimension; d, the smallest dimension). All experiments were approved by Ethical Committee of the institute. The functional activity of the effectors of immuno- logic response was studied in experimental animals one day prior to tumor transplantation and on days 6 and 34 after tumor cell transplantation (TCT) (as well as in control animals). The functional activity of peritoneal macrophages (PMp) was evaluated by the level of oxygen-dependent metabolism and cytotoxicity. Oxygen-dependent metabolism was determined by reduction of tet- razolium nitroblue (NBT) [18]. Optical density of reduced NBT was analyzed using microplate photom- eter “Reader”(Labotech, Latvia) at the wavelength of 630 nm. The cytotoxic activity of PMp was evaluated by MTT colorimetric test [19, 20]. The cells of allogenic tumor served as target cells. Optical density was measured using microplate photometer “Reader” (Labotech, Latvia) at the wavelength of 545 nm. Specific killing of target cells was calculated by formula: CA = (1 – (Em – Ee)/(Et – Ec)) × 100%, where E is mean absorbance of the wells: Em — the wells with mixture of the target and effector cells; Ee — the wells with the effector cells; Et — the wells with the target cells; Ec — control of medium [20]. The cytotoxic activity of spleen mononuclear cells was evaluated by MTT colorimetric test [20, 21]. Mono- nuclear cells were isolated by standard method from spleen by centrifugation of cell suspension (obtained after homogenisation of spleen tissue in Potter’s ho- mogenizer) in the Ficoll-verografin density gradient (ρ = 1.077). Cell suspensions with viability higher then 80% were used [22]. K562 cells were used as target cells, sensitive to natural killer cells (NK). The ratio be- tween effector cells and target cells was 1/50; duration of co-incubation was 18 h. Then, 20 μl of MTT solution (5 mg/ml MTT in PBS) were added to each well and the plates were incubated for 4 h at 37 ˚C. In order to stop the reaction, 100 μl DMSO were then added with vig- orous mixing. Optical density of incubation mixture in the wells was measured using microplate photometer “Reader” (Labotech, Latvia) at the wavelength of 545 nm. Cytotoxic activity of spleen mononuclear cells was calculated by the foresaid formula. Anticancer efficacy of lectin was evaluated by ana- lysis of tumor growth dynamics and average life span (ALS) of experimental animals using tumor growth in- hibition index (TGI) and ALS modulation index (MI) [23, 24]. The indices were calculated using the formulas: TGI = ((V – Vk)/Vk) × 100%, where V is mean tumor volume calculated for experimental groups treated by CL; Vk is mean tumor volume in the control group [23]. MI = ((E – K)/K) × 100%, where E is mean ALS of groups treated by CL; K is mean ALS in control group [24]. Statistical analysis of the data was performed by standard methods using Student’s t-test. RESULTS AND DISCUSSION The inhibition of sarcoma 37 growth was assessed in the animals treated with CL isolated from meta- bolic products of В. subtilis В-7025 in prophylactic or combined schedule. As seen in Fig. 1, such treatment resulted in tumor growth inhibition. On day 28 after tumor cell transplantation (TCT), TGI in mice from experimental group I was 66%, while in mice preven- tively treated with lectin (experimental group II) TGI amounted to 50.5%. The average life span (ALS) of experimental animals relative to untreated controls increased (Table). 3 2 1 0 0,2 0,4 0,6 0,8 1 1,2 1,4 1,6 7 14 25 28 32 Days Tu m or vo lu m e, c m 3 Fig. 1. Effect of prophylactic and combined use of lectin on the growth of sarcoma 37 in tumor bearing mice. 1 — administration of CL before and after tumor cell transplantation, 2 — administra- tion of CL before tumor cell transplantation, 3 — control Table. Average life span of mice with transplanted sarcoma 37 upon pro- phylactic and combined treatment with bacterial lectin Group Number of mice Dosage and method of administration of lectin, mg/animal ALS, M ± m t MI,% CL→TCT→CL 8 0.2 before and 0.05 after TCT, s/c 85.1 ± 9.3* 3.6 69.5 CL→TCT→PS 7 0.2, s/c 71.1 ± 4.5* 4.1 41.6 Control 8 - 50.2 ± 2.3 - - Notes: *— p < 0.05 compared to control group. The effects of CL on tumor growth in mice may be caused by two reasons: activation of antitumor defense and direct cytotoxic action of lectin on tumor cells. We have attempted to analyze CL effects on the activity of 256 Experimental Oncology 32, 254–257, 2010 (December) PMp in tumor-bearing animals. Macrophages repre- sent an important component of antitumor resistance. According to the literature data [25, 26], the lectins of different origin activate both peripheral blood mono- cytes and resident macrophages. In our experiment four injections of bacterial lectins to intact animals at a dose of 0.2 mg have led to activation of these effector cells. Sarcoma 37 transplantation additionally stimu- lated their activity registered on day 6 after TCT. This trend persists even on day 34 after TCT in the case of the combined schedule of the treatment, although the differences were not significant (data are not shown). On day 6 after tumor transplantation, in both ex- perimental groups the index of cytotoxic activity of PMp increased more than twice compared to that in tumor-bearing control (Fig. 2). On day 34, cytotoxicity of macrophages was similar to control values. These results allow us to suppose that at the late stages of tumor growth macrophages-suppressors that inhibit macrophage-mediated cytotoxicity and promote tu- mor growth, began to be involved in the process. -40 0 40 80 120 160 6 34 Day after TCT Cy to to xic ity , % Fig. 2. Effect of prophylactic and combined use of lectin on cytotoxic activity of peritoneal macrophages from mice bear- ing sarcoma 37. І — administration of CL before and after TCT, ІІ — administration of CL before TCT, ІІІ — tumor-bearing control It is known that the development of tumor growth suppresses the functional activity of splenocytes, includ- ing natural killer cells. As one may see in Fig. 3, in tumor- bearing mice an immunosuppressive effect of tumor toward these effector cells of natural immunity could be observed manifesting by the decreased ability of spleen mononuclear cells from control animals to cause lysis of target cells. * ** I ** II III IIIIV IV 0 5 10 15 20 25 30 6 34 Day Cy to to xic ity ,% Fig. 3. Effect of prophylactic and combined use of lectin on cytotoxic activity of mononuclear splenocytes from mice bear- ing sarcoma 37. І — administration of CL before and after TCT, ІІ — administration of CL before TCT, ІІІ — tumor bearing control, IV — intact control In prophylactic use of lectin, on day 6 after TCT elevated cytotoxicity of splenocytes against sensitive К562 cells was evident. However, the most potent stimu- lating effect of prophylactic and combined use of lectin on cytotoxic activity of spleen cells was revealed on day 34 after TCT: the cytotoxicity of macrophages of experi- mental animals was more than twice higher than those of control tumor-bearing animals. Since NK-sensitive K562 cells were used as target cells, we suppose that NK cells were predominantly responsible for the observed cytotoxic effect of spleen mononuclear cells. Neverthe- less, other subpopulations of spleen lymphoid cells can also be responsible for negligible part of cytotoxic effect of spleen cells against target cells used in the study. Therefore, antitumor effect of lectin administration is accompanied by activation of immunologic reactivity of mice. Stimulating influence of lectins on tumor-bearing animals at the early stage of tumor growth has been reg- istered for functional activity of peritoneal macrophages, and at the late stage — for spleen mononuclear cells. In oncological practice bacterial lectins are used as the components of antitumor vaccines and as adjuvants but not as an individual anticancer or immunomodulating preparations. Nevertheless, high cytotoxicity against ma- lignant cells has been already shown for several lectins of plant and fungal origin [3–5, 27, 28]. Antiproliferative activity of lectins is often combined with their ability to stimulate distinct reactions of immune system [2, 3, 6–8, 26]. It has been previously shown that В. subtilis B-7025 lectins are highly cytotoxic in vitro against tumor cells of different genesis [17]. We also have described [15] significant inhibitory preventive influence of lectins from В. subtilis B-7025 in vivo on tumor growth and metastasizing in mice. This antitumor effect of bacterial lectin is very similar to that revealed for Aloe vera lectin [29] and mistletoe lectins [5]. In present work immunomodulating properties of cytotoxic lectin in sarcoma 37 bearing mice in dynamics were displayed. This allows us to assume that antitumor effect of CLs like some other lectins is realized via not only its cytotoxic action against tumor cells but also via enhancing impact on innate immunity. According to our data, the combined schedule of В. subtilis lectins admin- istration seems to be more effective than prophylactic one to provide complete realization of all beneficial potentials of lectins. REFERENCES 1. Rudiger H, Siebert HC, Solis D, et. al. Medici- nal chemistry based on the sugar code: Fundamentals of lectinology and experimental strategies with lectins as targets. Curr Med Chem 2000; 7: 389–416. 2. Gabius HJ. Probing the cons and pros of lectin-induced immunomodulation: Case studies for the mistletoe lectin and galectin-1. Biochimie 2001; 83: 659–66. 3. Boneberg EM, Hartung T. Mistletoe lectin-1 increases tumor necrosis factor-α release in lipopolysaccharide-stimu- lated whole blood via inhibition of interleukin-10 production. J Pharmacol Exp Therapeut 2001; 3: 996–1000. 4. Braun JM, Ko HL, Schierholz JM, et. al. Application of standardized mistletoe extracts augment immune response Experimental Oncology 32, 254–257, 2010 (December) 257 and down regulates metastatic organ colonization in murine models. Cancer Lett 2001; 170: 25–31. 5. Hajtó T, Hostanska K, Berki T, et. al. Oncopharmaco- logical Perspectives of a Plant Lectin (Viscum album Aggluti- nin-I): Overview of Recent Results from In vitro Experiments and In vivo Animal Models, and Their Possible Relevance for Clinical Applications. Alternat Med 2005; 1: 59–67. 6. Braun JM, Gemmell CG, Beuth J, et. al. Respiratory burst of human polymorphonuclear leukocytes in response to the galactoside-specific mistletoe lectin. Zentralbl Bakteriol 1995; 283: 90–4. 7. Lyu SY, Park WB. Mistletoe lectin modulates intestinal epithelial cell-derived cytokines and B cell IgA secretion. Arch Pharm Res 2009; 3: 443–51. 8. Bhutia SK, Mallick SK, Maiti TK. In vitro immunos- timulatory properties of Abrus lectins derived peptides in tumor bearing mice. Phytomedicine 2009; 8: 776–82. 9. Taise K, Shigeaki H, Hiroshi S, et al. Tumor vaccine containing lectin-tumor cell complex. Patent 53044613 JP, MPK A61K 35/78, 1998. 10. Sugahara T, Ohama Y, Fukuda A, et. al. The cytotoxic effect of Eucheuma serra agglutinin (ESA) on cancer cells and its application to molecular probe for drug delivery system using lipid vesicles. Cytotechnology 2001; 1–3: 93–9. 11. Sakuma S, Yano T, Masaoka Y, et. al. In vitro/in vivo biorecognition of lectin-immobilized fluorescent nanospheres for human colorectal cancer cells. J Control Release 2009; 1: 2–10. 12. Potebnya GP, Tanasienko OA, Titiva GP, et al. Specific- ity and biological activity of cytotoxic lectins synthesized by Bacillus subtilis B-7025. Exp Oncol 2002; 2: 250–2. 13. Potebnya GP, Tanasienko OA, Lisovenko GP, et al. Ef- ficacy of anticancer vaccines on the base of cytotoxic lectins of bacterial origin. Ukr Chemother Zh 2002; 4: 29–32 (in Russian). 14. Potebnya GP, Tanasienko OA, Shlyakhovenko VO. Influence of anticancer vaccine on metastasis of Lewis lung carcinoma at different schemes of introduction. Dop NAS Ukr 1999; 9: 76–80 (in Ukrainian). 15. Tanasienko OA, Titova GP, Rudyk MP, et al. Induc- tion of antitumor resistance in mice using cytotoxic lectins of bacterial origin. Microbiol Biotechnol 2010; 2: 59–66 (in Ukrainian). 16. Potebnya GP, Tanasiyenko OA, Cheremshenko NL, et al. Regularities of cytotoxic lectines biosynthesis by Bacillus subtilis B-7025 culture, growing on different media. Ukr Che- mother Zh 2002; 13: 54–7 (in Russian). 17. Potebnya GP, Tanasienko OA, Lisovenko GP, et al. The use of cytotoxic lectins of bacterial origin for immunotherapy of experimental tumors. In: Pozur V.K., ed. Structure and biologic activity of bacterial biopolymers. Kyiv: VPC Kiev University 2003; 235–304 pp (in Ukrainian). 18. Perederiy VG, Zemskov AM, Bychkova NG, et al. Im- mune status, principles of its evaluation and correction of im- mune mailfunction. Kyiv: Zdorovya, 1995. 211 pp (in Russian). 19. Fedosova NI, Usach ОМ, Yudina OYu, et al. Influence of antitumor vaccines on the activity of macrophages. Naukovi Zapiski Kyiv-Mohyla Acad 2002; 20: 441–4 (in Ukrainian). 20. Niks M, Otto M. Towards an optimized MTT assay. J Immunol Meth 1990; 1: 149–51. 21. Shpakova AP, Pavlova KS, Bulycheva TI. MTT-colori- maetric method for measuring the cytotoxic activity of natural killer cells. Clin Labor Diagnost 2000; 2: 20–3 (in Russian). 22. G Frimel’, ed. Immunological methods. Moskow: Meditsina 1987; 472 p (in Russian). 23. Dasyukevich OI, Solyanik GI. Comparative study of anticancer efficacy of aсonitine-containing agent BC1 against ascite and solid forms of Ehrlich’s carcinoma. Exp Oncol 2007; 4: 317–9. 24. Pozur VV, Skivka LM, Potebnya GP. Influence of autovaccine supplemented with peptidoglycan Staphylococ- cus aureus Wood 46 on the growth dynamic of experimental tumors in mice. The Reports of NAS of Ukraine 2008; 12: 145–9 (in Ukrainian). 25. Kishko IaH, Vasylenko MI, Kovalenko EO, et al. Influence of Bacillus subtilis sp. lectin on functional activity of phagocytes. Mikrobiol Z 1998; 1: 36–42 (in Russian). 26. Yoon TJ, Yoo YC, Kang TB, et al. Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res 2003; 10: 861–7. 27. Damian L, Fournier D, Winterhalter M, et al. De- termination of thermodynamic parameters of Xerocomus chrysenteron lectin interactions with N-acetylgalactosamine and Thomsen-Friedenreich antigen by isothermal titration calorimetry. BMC Biochem 2005; 6:11. 28. Ng TB, Ngai PHK, Xia L. An agglutinin with mitogenic and antiproliferative activities from the mushroom Flammulina velutipes. Mycologia 2006; 2: 167–71. 29. Akev N, Turkay G, Can A, et al. Tumour preventive ef- fect of Aloe vera leaf pulp lectin (Aloctin I) on Ehrlich ascites tumours in mice. Phytother Res 2007; 11: 1070–5. Copyright © Experimental Oncology, 2010